ZGN-1061
Overview[edit | edit source]
ZGN-1061 is a peptide-based drug that has been investigated for its potential use in treating metabolic disorders, particularly type 2 diabetes mellitus. It is designed to act as an agonist of the insulin receptor, thereby mimicking the effects of insulin and promoting glucose uptake in cells.
Mechanism of Action[edit | edit source]
ZGN-1061 functions by binding to the insulin receptor on the surface of target cells. This binding activates the receptor's tyrosine kinase activity, leading to a cascade of intracellular signaling events. These events include the activation of the PI3K/AKT pathway, which ultimately results in the translocation of GLUT4 transporters to the cell membrane, facilitating the uptake of glucose from the bloodstream into the cell.
Development and Clinical Trials[edit | edit source]
ZGN-1061 was developed as a second-generation insulin receptor agonist, following the earlier development of peptide-based drugs with similar mechanisms. The drug underwent several phases of clinical trials to assess its efficacy and safety in patients with type 2 diabetes.
Potential Benefits[edit | edit source]
The primary benefit of ZGN-1061 is its ability to lower blood glucose levels in patients with insulin resistance. By mimicking the action of insulin, it helps in maintaining glycemic control and reducing the risk of hyperglycemia.
Challenges and Considerations[edit | edit source]
While ZGN-1061 shows promise, there are challenges associated with its use. These include potential side effects such as hypoglycemia, as well as the need for subcutaneous injections, which may affect patient compliance. Additionally, the long-term effects of chronic administration are still under investigation.
Chemical Structure[edit | edit source]
ZGN-1061 is a synthetic peptide with a specific sequence designed to optimize its binding affinity and selectivity for the insulin receptor. The structure of ZGN-1061 is crucial for its function, as it determines the drug's ability to interact with the receptor and initiate the desired signaling pathways.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
